john mascarenhas, ash 2019: treating myelodysplastic syndromes and myeloproliferative neoplasms
Published 4 years ago • 400 plays • Length 4:43Download video MP4
Download video MP3
Similar videos
-
7:57
srdan verstovsek, ash 2019: individualized management of myeloproliferative neoplasms
-
0:56
john mascarenhas, md, on the individualized management of myeloproliferative neoplasms
-
1:06
john mascarenhas, md, on the role of molecular analysis in myeloproliferative neoplasms
-
1:14
john mascarenhas, md, on jak inhibitors & combination therapies in myeloproliferative neoplasms
-
8:09
abdulraheem yacoub, ash 2019: novel agents for the treatment of pv and mf
-
2:00
dr. mascarenhas on approved and emerging treatment options in myelofibrosis
-
2:22
what are the benefits of mpn inhibitor treatment?
-
4:59
john mascarenhas, md, ms: continuing to evaluate pacritinib for myelofibrosis
-
5:09
myelodysplastic syndromes (mds): symptoms, diagnosis, and treatment
-
3:21
what is mds or myelodysplastic syndrome in hindi | is mds a blood cancer | dr karuna kumar
-
14:39
q&a - myelodysplastic syndrome (mds)
-
10:41
myelodysplastic syndrome (mds) - what is the treatment?
-
4:04
which tests do you need following an mpn diagnosis?
-
1:40
what is personalized medicine for et, pv & mf?
-
4:35
patient considerations that impact mpn treatment decisions
-
1:30
the safety profile of imetelstat in myeloid malignancies
-
4:53
what questions should patients ask about mpn test results?
-
3:38
myelodysplastic syndromes (mds) with dr melita kenealy
-
1:47
the evolution of myelofibrosis treatment and modern-day management
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
4:28
predicting prognosis in myelodysplastic syndromes
-
4:04
quality of life in transfusion-dependent mds